Eli Lilly and Co. subsidiary Elanco US Inc. has completed the acquisition of the U.S. feline, canine and rabies vaccines portfolio from Boehringer Ingelheim Vetmedica Inc. and its manufacturing/research and development site.
This adds to Elanco’s portfolio of vaccines including Bordetella, Lyme disease, feline leukemia, rabies and parvovirus.
"With a growing portfolio addressing both prevention and treatment of disease, Elanco is now able to offer our U.S. customers a comprehensive suite of solutions to some of pets' most common issues," Eric Graves, president of Elanco's North American operations, said. "These new offerings will come with the Elanco expertise that veterinarians and pet owners have come to know and trust, including pet health case management, technical support, and resources for supporting the human-animal bond."
The BIVI portfolio, including the estimated cost for acquired inventory, was acquired by Elanco for approximately $885 million and closed on Jan. 3.
The canine product lines include Duramune, Duramune Lyme, Bronchi-Shield, and ULTRA Duramune. The feline product lines are Fel-O-Vax, ULTRA Fel-O-Vax and Fel-O-Guard. The only product in the rabies line was Rabvac.
Elanco promises the vaccine supply will be available immediately to vets so treatments for cats and dogs will not be interrupted.
